The Corynebacterium granulosum-derived P40 immunomodulator exerts a synergistic effect on the activity of antiviral drugs in the treatment of experimental viral infections.
Comparative studies have been carried out on the effects on 2 viral-infection models (Herpes virus and influenza virus) of treatments consisting of either C. granulosum-derived immunomodulator P40, or of vidarabin or amantadine as antiviral drugs, or of combinations of vidarabin or amantadine with P40. According to the modalities of administration of the P40 or of the antiviral drugs, the anti-infectious effect was more or less marked. In contrast, the combinations of P40 and antiviral drugs did not result in a cumulative effect but in significant synergy of the effects of each component of the treatments.
Fattal-German
M
M
Unité d'Immunochimie des Protéines, Institut Pasteur, Paris, France.
Bizzini
B
B
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000547:Amantadine / Q000008:administration & dosage; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D003352:Corynebacterium / Q000276:immunology; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy / Q000628:therapy; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy / Q000628:therapy; D014740:Vidarabine / Q000008:administration & dosage; D014777:Virus Diseases / Q000188:drug therapy / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D000547:Amantadine; D014740:Vidarabine